Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after ...
Amgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data ...
Zacks.com on MSN5d
Amgen Shrugs Off Bone Density Concerns Related to Obesity CandidateAmgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.
On Tuesday, a Cantor analyst wrote that additional data from Amgen’s experimental weight loss injection, MariTide, suggests a ...
(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...
Analyzing Amgen's stock drop, management's response, and potential for growth in GLP-1 candidate MariTide in a volatile ...
Analysts chewed over early data showing the highest dose of Amgen's MariTide was linked to roughly 4% loss of bone mineral density over 12 weeks.
As an aside, in the tech space, see What’s Happening With Snap Stock? Although the recent Amgen update didn’t bode well with ...
Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback